- Home
- PSTL vs NNNN Comparison
PSTL vs NNNN Comparison
Compare PSTL & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- NNNN
- Stock Information
- Founded
- PSTL 2018
- NNNN 2021
- Country
- PSTL United States
- NNNN Germany
- Employees
- PSTL N/A
- NNNN N/A
- Industry
- PSTL Real Estate Investment Trusts
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PSTL Real Estate
- NNNN Health Care
- Exchange
- PSTL Nasdaq
- NNNN Nasdaq
- Market Cap
- PSTL 311.3M
- NNNN 267.7M
- IPO Year
- PSTL 2019
- NNNN 2025
- Fundamental
- Price
- PSTL $12.60
- NNNN $6.43
- Analyst Decision
- PSTL Strong Buy
- NNNN
- Analyst Count
- PSTL 1
- NNNN 0
- Target Price
- PSTL $16.50
- NNNN N/A
- AVG Volume (30 Days)
- PSTL 199.4K
- NNNN 29.4K
- Earning Date
- PSTL 04-30-2025
- NNNN 01-01-0001
- Dividend Yield
- PSTL 7.68%
- NNNN N/A
- EPS Growth
- PSTL 176.54
- NNNN N/A
- EPS
- PSTL 0.28
- NNNN 0.06
- Revenue
- PSTL $81,235,000.00
- NNNN $8,185,146.00
- Revenue This Year
- PSTL $14.67
- NNNN N/A
- Revenue Next Year
- PSTL $11.15
- NNNN N/A
- P/E Ratio
- PSTL $44.65
- NNNN $114.60
- Revenue Growth
- PSTL 23.36
- NNNN 21.95
- 52 Week Low
- PSTL $12.26
- NNNN $5.18
- 52 Week High
- PSTL $15.15
- NNNN $7.82
- Technical
- Relative Strength Index (RSI)
- PSTL 35.52
- NNNN N/A
- Support Level
- PSTL $12.53
- NNNN N/A
- Resistance Level
- PSTL $12.77
- NNNN N/A
- Average True Range (ATR)
- PSTL 0.32
- NNNN 0.00
- MACD
- PSTL -0.05
- NNNN 0.00
- Stochastic Oscillator
- PSTL 23.68
- NNNN 0.00
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.